Fairvalue-Calculator Fairvalue-Calculator
EN DE

Greenway Greenhouse Cannabis Corporation (GWAYF) Fair Value & Analysis

Healthcare · US · Market cap $13.4M

Price$0.1005
Fair Value$0.0400
Upside-60.2%
Quality95/100
Evidence: Medium Range $0.0200 – $0.0600

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Greenway Greenhouse Cannabis Corporation (GWAYF) currently trades at $0.1005, while our model-based Fair Value estimate is $0.0400 — implying the stock looks roughly 60.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Greenway Greenhouse Cannabis Corporation engages in the cultivation, processing, sale, bulk package, and wholesale of dry bud cannabis. The company was incorporated in 2018 and is headquartered in Kingsville, Canada. Greenway Greenhouse Cannabis Corporation is a subsidiary of Sunrite Greenhouses Ltd.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Greenway Greenhouse Cannabis Corporation (GWAYF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0400 versus a price of $0.1005 — about −60% (overvalued). Model-based estimate, not financial advice.
What is the fair value of GWAYF?
Our 21-model fair value for Greenway Greenhouse Cannabis Corporation is $0.0400 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1005.
What is the quality score of GWAYF?
Greenway Greenhouse Cannabis Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.